Estudo publicado no Lancet Oncology relata dados de sobrevida em 5 anos do estudo WSG-ADAPT-HER2+/HR, que avalia o de-escalonamento do tratamento neoadjuvante em pacientes com câncer de mama precoce HER2-positivo, HR-negativo, abordando o efeito da resposta patológica completa, resposta terapêutica precoce e subtipo molecular. O trabalho está em pauta no PODCAST ONCONEWS, com apresentação de Silvio Bromberg e Daniel Gimenes. Os especialistas discutem ainda os resultados de longo prazo do Danish Breast Cancer Group Internal Mammary Node Study, que avalia a irradiação dos linfonodos de cadeia mamária interna em pacientes com câncer de mama precoce linfonodo positivo. Confira.
Referências:
- Nitz U, Gluz O, Graeser M, Christgen M, Kuemmel S, Grischke EM, Braun M, Augustin D, Potenberg J, Krauss K, Schumacher C, Forstbauer H, Reimer T, Stefek A, Fischer HH, Pelz E, Zu Eulenburg C, Kates R, Wuerstlein R, Kreipe HH, Harbeck N; WSG-ADAPT investigators. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2022 Apr 8:S1470-2045(22)00159-0. doi: 10.1016/S1470-2045(22)00159-0. Epub ahead of print. PMID: 35405088.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00159-0/fulltext - Lise B.J. Thorsen, MD, PhD; Jens Overgaard, MD, DMSc; Louise W. Matthiessen, MD, PhD; Martin Berg, MSc; Lars Stenbygaard, MD; Anders N. Pedersen, MD, PhD; Mette H. Nielsen, MD, PhD; Marie Overgaard, MD; and Birgitte Vrou Offersen, MD, PhD on behalf of the DBCG Radiotherapy Committee - Internal Mammary Node Irradiation in Patients With Node-Positive Early Breast Cancer: Fifteen-Year Results From the Danish Breast Cancer Group Internal Mammary Node Study - DOI: 10.1200/JCO.22.00044 Journal of Clinical Oncology - Published online April 08, 2022.
https://ascopubs.org/doi/abs/10.1200/JCO.22.00044
--
